Analyst Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Omeros and keeping the price target at $9.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Folkes has given his Buy rating due to a combination of factors surrounding Omeros’s strategic advancements with narsoplimab. The drug, a MASP-2 inhibitor, is under review for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in the U.S., with a PDUFA action date set for December 2025. The company’s preparations for potential FDA approval, including building a specialized salesforce and engaging with payers, indicate a strong commitment to commercializing narsoplimab effectively.
Additionally, Omeros’s submission of a Marketing Authorization Application to the European Medicines Agency, which is currently under review, suggests a promising outlook for approval in Europe. The company’s past success in product commercialization and the strategic focus on narsoplimab are expected to create significant value. This focus is anticipated to not only drive cash flow but also enable reinvestment in paused pipeline programs, thereby unlocking further value in the long term. The potential approval of narsoplimab is seen as a validation of Omeros’s capability to execute its broader pipeline strategy, enhancing investor confidence in the stock.
Folkes covers the Healthcare sector, focusing on stocks such as Omeros, Eupraxia Pharmaceuticals, and Trevi Therapeutics. According to TipRanks, Folkes has an average return of -5.2% and a 36.23% success rate on recommended stocks.